Results 211 to 220 of about 220,141 (335)

Mullins' syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra [PDF]

open access: yes, 2015
A.L. Manson   +12 more
core   +1 more source

Third‐Generation EGFR‐TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study

open access: yesCancer Science, EarlyView.
This study was the largest sample size of first‐line third‐generation TKIs combined chemotherapy among advanced EGFRm NSCLC patients in the real world. It was never reported that aumolertinib and furmonertinib showed comparable PFS benefits to osimertinib in combination with chemotherapy. The overall safety profile remained acceptable. ABSTRACT FLAURA2
YuQin Jiang   +9 more
wiley   +1 more source

A Case of Parvovirus B19 Infection Mimicking Mumps Virus Infection in a Healthy Adult. [PDF]

open access: yesEur J Case Rep Intern Med
Sedogawa H   +5 more
europepmc   +1 more source

Impact of Door to Needle Time of Antibiotics Administration on Outcome in Cancer Patients with Febrile Neutropenia

open access: diamond
Hafsah Iqbal   +4 more
openalex   +2 more sources

Neutropenia during sodium valproate treatment. [PDF]

open access: bronze, 1979
J Jaeken   +5 more
openalex   +1 more source

Combinatorial targeting of MYC/BCL2‐associated vulnerabilities in high‐grade B‐cell lymphoma

open access: yes
British Journal of Haematology, EarlyView.
Giulio Donati   +6 more
wiley   +1 more source

Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG‐1901 Study

open access: yesCancer Science, EarlyView.
The KYUCOG‐1901 prospective multicenter study evaluated radium‐223 in 93 Japanese patients with bone‐metastatic castration‐resistant prostate cancer. Ra‐223 was well tolerated, produced meaningful declines in ALP, and yielded a median overall survival of 23.0 months. Early initiation in patients with lower disease burden and integration with subsequent
Masaki Shiota   +12 more
wiley   +1 more source

Perioperative Nivolumab in Resectable Non‐Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T

open access: yesCancer Science, EarlyView.
ABSTRACT In the randomized phase III CheckMate 77T study, perioperative nivolumab showed statistically significant and clinically meaningful improvement in event‐free survival (EFS) vs. placebo in patients with resectable, non‐metastatic non‐small cell lung cancer (NSCLC).
Fumihiro Tanaka   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy